Condition: Psoriatic Arthritis · Sponsor: Hansoh BioMedical R&D Company
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.
This description comes directly from the study's public registry record.
Hejian Zou, PhD · +86-13311881366 · hjzou@unirheuma.org
Always discuss trial participation with your own doctor first.
| Huashan Hospital affiliated to Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06176508